Tag Archives: Horizon Pharma

December, 2018

27 December
FDA Expands Approval of Horizon’s Ravicti Oral Liquid for Use in Newborns Living with Urea Cycle Disorder

DUBLIN–(BUSINESS WIRE)–Horizon Pharma plc (NASDAQ: HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to expand the age range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to include infants younger than two months of age living with a urea cycle disorder (UCD). …
Share

8 May
Horizon Acquires River Vision and its Late-Stage Rare Eye Disease Drug for $145 Million

DUBLIN, Ireland, May 08, 2017 (GLOBE NEWSWIRE) — Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has agreed to acquire River Vision Development Corp. (“River Vision”) and …
Share

9 December
Horizon Pharma’s Actimmune Fails in Late-Stage Study in Friedreich’s Ataxia

DUBLIN, Ireland, Dec. 08, 2016 (GLOBE NEWSWIRE) — Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the Phase 3 trial, STEADFAST (Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich’s Ataxia study), evaluating ACTIMMUNE® …
Share

12 September
Horizon to Acquire Rare Disease Company Raptor Pharmaceutical for $800 Million

DUBLIN, Ireland and NOVATO, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) — Horizon Pharma plc (NASDAQ:HZNP) and Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced the companies have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Raptor Pharmaceutical Corp. common stock for …
Share

8 July
Horizon Pharma Offers to Acquire Depomed in a $3 Billion Deal

DUBLIN, IRELAND — (Marketwired) — 07/07/15 — Horizon Pharma plc (NASDAQ: HZNP) Transaction would generate significant revenue and operating synergies, tax savings and would also be immediately and substantially accretive to Horizon’s adjusted diluted earnings per share Projected full-year pro forma combined 2015 net sales and adjusted EBITDA would be …
Share